CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-27 | Somaiya Mayur Ian Chief Financial Officer | Sale 10b5-1 | −13,304 | 38,000 | ||
| 2025-01-27 | Somaiya Mayur Ian Chief Financial Officer | Option exercise · Option (Right to Buy) 10b5-1 | −46,983 | 777,714 | ||
| 2025-01-27 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +104,174 | 148,174 | ||
| 2025-01-27 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −80,359 | 67,815 | ||
| 2025-01-27 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −23,815 | 44,000 | ||
| 2025-01-27 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −104,174 | 321,971 | ||
| 2025-01-07 | Smither John W Director | Grant or award | +6,960 | 6,960 | ||
| 2025-01-07 | McKenna Mark C. Director | Grant or award | +6,960 | 6,960 | ||
| 2025-01-07 | Lewis William Director | Grant or award | +6,960 | 6,960 | ||
| 2025-01-07 | van der Kamp Hilde Johanna Director | Grant or award | +6,960 | 6,960 | ||
| 2025-01-07 | LANGE LOUIS G Director | Grant or award | +6,960 | 6,960 | ||
| 2025-01-07 | Kooij Louise Frederika Chief Accounting Officer | Grant or award | +15,000 | 15,000 | ||
| 2025-01-07 | Davidson Michael H. Chief Executive Officer | Grant or award | +123,529 | 123,529 | ||
| 2025-01-07 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Grant or award | +34,000 | 34,000 | ||
| 2025-01-07 | Audet Juliette Berangere Chief Business Officer | Grant or award | +14,000 | 15,104 | ||
| 2025-01-07 | JONES WILLIAM A JR Chief Commercial Officer | Grant or award | +43,000 | 43,000 | ||
| 2025-01-07 | Kling Douglas F Chief Operating Officer | Grant or award | +44,000 | 44,000 | ||
| 2025-01-07 | Somaiya Mayur Ian Chief Financial Officer | Grant or award | +38,000 | 38,000 | ||
| 2025-01-06 | Smither John W Director | Grant or award · Option (right to buy) | +32,500 | 32,500 | ||
| 2025-01-06 | McKenna Mark C. Director | Grant or award · Option (right to buy) | +32,500 | 32,500 |
Page 12 of 15 · 300 trades